Menu
Back to Journals » Therapeutics and Clinical Risk Management » Volume 8
Consequences of neurologic lesions assessed by Barthel Index after Botox® injection may be underestimated
Authors Dionyssiotis Y, Kiourtidis D, Karvouni, Kalionzoglou A, Kliafas I
Received 15 April 2012
Accepted for publication 6 July 2012
Published 19 October 2012 Volume 2012:8 Pages 385—391
DOI https://doi.org/10.2147/TCRM.S32974
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 3
Y Dionyssiotis,1,2 D Kiourtidis,3 A Karvouni,3 A Kaliontzoglou,3 I Kliafas3
1Medical Department, Rehabilitation Center Amyntaio, General Hospital of Florina, Amyntaio, Florina, 2Physical Medicine and Rehabilitation Department, Rhodes General Hospital, Rhodes, Dodecanese, 3Neurologic Department, Rhodes General Hospital, Rhodes, Dodecanese, Greece
Purpose: The aim of this study was to investigate whether the consequences of neurologic lesions are underestimated when the Barthel Index (BI) is used to assess the clinical outcome of botulinum toxin injection.
Patients and methods: The records for all in- and outpatients with various neurologic lesions (stroke, multiple sclerosis, spinal cord injury, traumatic brain injury, and so forth) who had been referred to the authors’ departments and who had received botulinum toxin type A (Botox®) for spasticity within a 4-year period (2008–2011) were examined retrospectively. BI data were collected and analyzed.
Results: The BI score was found to have increased in follow-up assessments (P = 0.048). No correlation was found between the degree of spasticity and the BI score.
Conclusion: The specific injection of Botox in patients with neurologic lesions was not strongly correlated with a significant functional outcome according to the BI. The results of this study suggest that clinicians need to look at other measurement scales for the assessment of significant outcomes of Botox in the rehabilitation process after neurologic lesions.
Keywords: botulinum toxin type A, spasticity, stroke, multiple sclerosis
© 2012 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.